JOE WOODY is President and Chief Executive Officer of Acelity, a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited.
Acelity’s innovative and complementary product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. With approximately $1.9 billion in revenue, Acelity is the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity products are available in more than 80 countries.
Mr. Woody joined Kinetic Concepts (KCI) in 2011 and successfully led the company’s transition from a public-to-private corporation, introduced the high performance management system across the organization and established KCI as the global leader in transformational healing solutions. Under his leadership, KCI acquired MoMelan Technologies (2012), which led to fast-tracking the launch of the innovative CelluTome™ Epidermal Harvesting System (2013). Also in 2013, Mr. Woody strengthened the Company’s position in the global wound care industry with the acquisition of Systagenix, formerly the wound-care segment of Johnson & Johnson. This transformational acquisition diversified the Company’s product portfolio and increased the Company’s ability to offer best-in-class product offerings across the entire wound care continuum.
In 2014, Mr. Woody led efforts to integrate KCI, LifeCell and Systagenix into Acelity, a global corporation devoted to advancing the science of healing. Since the integration of Acelity, the company continues to transform under Mr. Woody’s leadership through the lens of a new four-part strategy: grow the core, focused innovation, geographic expansion and strategic acquisitions. With the new strategy in place, Acelity broadened its regenerative medicine portfolio by acquiring exclusive worldwide rights for the REVOLVE™ system, a fat processing technology used in both reconstructive and cosmetic procedures. With the acquisition of the SNAP™ business from Spiracur Inc. in 2015, Acelity now offers the broadest portfolio of disposable Negative Pressure Wound Therapy. The company ended fiscal year 2015 with five quarters of organic revenue growth under its belt.
With more than 20 years of experience in the healthcare sector, Mr. Woody held key executive roles at a number of industry-leading medical technology companies both in the US and Europe. Prior to his role at Acelity, Mr. Woody served as Global President, Vascular Therapies for Covidien, where he was responsible for the $2.6 billion acquisition and integration of ev3, a peripheral vascular and neurovascular business. He has also served in sales and executive leadership positions at Smith & Nephew, Alliance Imaging, Inc., Acuson and GE Medical Systems.
Mr. Woody serves on the Board of Directors of the Advanced Medical Technology Association (AdvaMed) and is Chair of the Wound Healing and Tissue Regeneration Sector. He also serves on the Board of Directors of the Medical Device Innovation Consortium (MDIC), consisting of world-class
representatives from the medical device industry, government, and patient groups. MDIC is the firstever public-private partnership created with the sole objective of advancing and improving medical device regulatory science and technology in partnership with the FDA. At present, he serves on the
board of Acelity’s parent company and was previously a board member at Systagenix. He is also dedicated to giving back to the communities in which Acelity employees live and work through volunteerism and philanthropy.
Mr. Woody holds a Bachelor’s degree from California State University, Fullerton.